Barbara Wojda, MD
Infectious Disease · Louisville, KYNPI 1225049661
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 75.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $4,959 and has fallen 97.6% since, to $119 in 2025.
Across 126 payments — averaging $55.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Astellas Pharma US Inc$390
- Insmed, Inc.$269
- Merck$243
- AbbVie$217
- Pfizer$200
- plus $378 from 9 others
What the payments were for
- Consulting fees$3,14045%
- Travel & lodging$1,46621%
- Food & beverage$2,35233%
- Education$711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 35 | $5,331 |
| Astellas Pharma US Inc | 18 | $390 |
| Insmed, Inc. | 13 | $269 |
| Merck | 14 | $243 |
| AbbVie | 13 | $217 |
| Pfizer | 11 | $200 |
| Melinta Therapeutics, LLC | 6 | $97 |
| Shionogi Inc | 4 | $90 |
| Paratek Pharmaceuticals, Inc. | 3 | $43 |
| Johnson & Johnson | 3 | $42 |
| Viiv Healthcare Company | 2 | $28 |
| Novavax Inc | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$4,691
How this compares
$7,028 in reported general payments places this provider in the 80th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 289 | $1,100,838 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 92 | $311,595 |
| RukobiaFostemsavir Tromethamine | 13 | $115,252 |
| DovatoDolutegravir Sodium/Lamivudine | 40 | $114,114 |
| CabenuvaCabotegravir/Rilpivirine | 18 | $109,663 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 31 | $109,530 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 25 | $97,698 |
| TivicayDolutegravir Sodium | 43 | $94,924 |
| DescovyEmtricitabine/Tenofov Alafenam | 17 | $36,487 |
| PrezcobixDarunavir/Cobicistat | 12 | $28,598 |
| IsentressRaltegravir Potassium | 14 | $27,388 |
| PifeltroDoravirine | 14 | $23,465 |
| Etravirine | 19 | $20,882 |
| ReyatazAtazanavir Sulfate | 11 | $15,130 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 14 | $3,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $5,331 | $1,235,023331 claims |
| Viiv Healthcare CompanyTriumeq, Rukobia, Dovato, Cabenuva, Tivicay | $28 | $745,549206 claims |
| MerckIsentress, Pifeltro | $243 | $50,85228 claims |
| Johnson & JohnsonPrezcobix | $42 | $28,59812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 100 infectious disease providers in Kentucky.
Other infectious disease in Louisville
- Julio RamirezLouisville$256K
- Martin GnoniLouisville$194K
- Paul SchulzLouisville$189K
- Tariq MehmoodLouisville$75K
- Anupama RaghuramLouisville$9K
- Benjamin KlausingLouisville$7K
- Kamran AkhtarLouisville$4K
- Forest ArnoldLouisville$4K
- Mark BurnsLouisville$3K
- Kenechukwu ObiokoyeLouisville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.